17ohp Compounded denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for 17ohp compounded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This as Not FDA-Approved

Blue Cross Blue Shield's coverage policies frequently require that a drug carry FDA approval for the prescribed indication as a condition of coverage. Compounded 17-hydroxyprogesterone caproate is prepared by a compounding pharmacy and is not itself an FDA-approved finished drug product. BCBS may also reference changes in the FDA's regulatory position regarding this compound. These two facts — compounded status and the FDA approval question — are the core of this denial.

This denial is specifically appealable on medical-necessity and formulary-exception grounds. Many BCBS coverage policies include provisions that allow coverage of compounded or unapproved agents when no appropriate FDA-approved alternative exists or when the compounded version is medically necessary for the individual patient. Your appeal must be built around those provisions.

## Federal Appeal Rights

• ACA §2719 external review: Independent review by an accredited IRO is available when internal appeal fails. The IRO applies clinical evidence standards, not simply FDA-label status. File within the deadline in your denial notice — typically around four months from the denial date per your plan documents.
• ERISA §503 (self-funded plans): Written, reasoned denial required; full and fair internal review guaranteed.
• Expedited review: Request simultaneously with standard review if clinical urgency applies.

## Concrete Appeal Steps

1. Obtain BCBS's published Coverage Medical Policy and identify whether it has any provision for compounded drugs or drugs without FDA approval when medically necessary. 2. Confirm whether any FDA-approved progesterone product is clinically interchangeable with the compounded formulation for your specific situation — your prescriber must address this directly. 3. Have your prescriber draft a letter addressing: (a) the FDA-approval landscape for this indication; (b) why the compounded formulation is medically necessary despite the absence of FDA approval; and (c) why any FDA-approved alternatives are not appropriate. 4. File an internal appeal within your plan's deadline, typically 180 days from the denial. 5. If denied, immediately request external review — IROs frequently overturn denials where the clinical evidence supports the treatment even absent FDA labeling.

## Documentation to Gather

• Diagnosis confirmation: Obstetric records establishing the clinical indication.
• Prior-treatment history: Records showing any FDA-approved agents tried or considered, with documented outcomes or clinical reasons they were not used.
• Clinical-severity documentation: Chart notes capturing risk factors and the prescriber's individualized clinical reasoning.
• Prescriber medical-necessity letter: Should directly address the FDA-approval issue, cite the applicable professional obstetric society's guidance on this compound (by organization name, not by citing specific numbers), and explain why the compounded formulation is the appropriate choice for this patient.
• Compounding pharmacy credentials: Documentation that the pharmacy operates under applicable compounding regulations (e.g., 503A or 503B status) may be relevant to BCBS's policy language.

## Criteria-Mapping Structure

| BCBS Policy Provision | Documentation Addressing Each Provision | |---|---| | Any exception language for compounded agents | Prescriber letter section addressing compounding rationale | | Any "medically necessary" override provision | Chart severity documentation + prescriber letter | | FDA-approval requirement and any stated exceptions | Prescriber letter addressing FDA landscape for this indication |

Always work from the current version of the BCBS policy — policies are updated and vary by affiliate. Your prescriber's office or a patient advocate can help obtain the applicable version.